

TRANSACTION GRANTED EARLY TERMINATION—Continued

ET date	Trans. No.	ET req status	Party name
		G G	E.W. Richardson. Pioneer Ford Sales Inc.

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay or Parcelleena P. Fielding, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202) 326-3100.

By Direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 98-10392 Filed 4-17-98; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of a Meeting of the National Bioethics Advisory Commission (NBAC)

SUMMARY: Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is given of a meeting of the National Bioethics Advisory Commission. The Commission will continue addressing (1) the protection of the rights and welfare of human subjects in research including research involving persons with disorders affecting decisionmaking capacity, and (2) issues in the research use of human biological materials. The meeting is open to the public and opportunities for statements by the public will be provided on May 19, 1998 from 11:30 am to 12 Noon.

Dates/times	Location
May 19, 1998, 8:30 am-5 pm and May 20, 1998, 8 am-3 pm.	Excelsior Ballroom-Thwing Student Center, Case Western Reserve University, 11111 Euclid Avenue, Cleveland, Ohio.

SUPPLEMENTARY INFORMATION: The President established the National Bioethics Advisory Commission (NBAC) on October 3, 1995 by Executive Order 12975 as amended. The mission of the NBAC is to advise and make recommendations to the National Science and Technology Council, its Chair, the President and other entities on bioethical issues arising from the research on human biology and behavior, and from the applications of that research and makes its

recommendations available to the public.

Public Participation

The meeting is open to the public with attendance limited by the availability of space on a first come, first serve basis. Members of the public who wish to present oral statements should contact Ms. Patricia Norris by telephone, fax machine, or mail as shown below at least 4 days before the meeting and as soon as possible. The Chair will reserve time for presentations by persons requesting to speak. The order of persons wanting to make a statement will be assigned on a first come, first serve basis. Individuals unable to make oral presentations can mail or fax their comments to the NBAC staff office at least five business days prior to the meeting for distribution to the Commission and inclusion in the public record. The Commission also accepts general comments at its website at bioethics.gov. Persons needing special assistance, such as sign language interpretation or other special accommodations, should contact NBAC staff at the address or telephone number listed below as soon as possible.

FOR FURTHER INFORMATION CONTACT: Ms. Patricia Norris, National Bioethics Advisory Commission, 6100 Executive Boulevard, Suite 5B01, Rockville, Maryland 20892-7508, telephone 301-402-4242, fax number 301-480-6900.

Henrietta D. Hyatt-Knorr,

Deputy Executive Director, National Bioethics Advisory Commission.

[FR Doc. 98-10386 Filed 4-17-98; 8:45 am]

BILLING CODE 4160-17-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, National Institute for Occupational Safety and Health Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

Name: Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH).

Time and Date: 9 a.m.-4 p.m., May 20, 1998.

Place: The Washington Court, Montpelier Room, 525 New Jersey Avenue, NW, Washington, DC 20001-1527.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Purpose: The BSC, NIOSH is charged with providing advice to the Director, NIOSH on NIOSH research programs.

Specifically, the Board shall provide guidance on the Institute's research activities related to developing and evaluating hypotheses, systematically documenting findings, and disseminating results.

Matters to be Discussed: Agenda items include a report from the Director of NIOSH; Update on Latex Allergy Activities; Hearing Loss Prevention Program; Hearing Loss Communications Campaign; Update on NIOSH Agriculture Program; State Surveillance Planning Update; Evaluating NIOSH Small Business Interventions; and future activities of the Board.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Dr. Bryan D. Hardin, Executive Secretary, BSC, NIOSH, 1600 Clifton Road, NE, m/s D-35, Atlanta, Georgia 30333. Telephone 404/639-3773, fax 404/639-2170, e-mail bdh1@cdc.gov.

Dated: April 13, 1998.

Nancy C. Hirsch,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-10296 Filed 4-17-98; 8:45 am]

BILLING CODE 4163-19-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Summary Date Component (SDC) of the National Child Abuse and Neglect Data System (NCANDS).

OMB No.: 0980-0229.

Description: This information collection implements the provision of the Child Abuse Prevention and Treatment Act (42 U.S.C. 5101 *et seq.*), as amended by Pub. L. 104-235, requiring that State agencies receiving the State child abuse and neglect grant

annually provide, "to the maximum extent practical," an annual data report. Data elements include the number of children reported for child abuse and neglect; the number of children for whom maltreatment was substantiated, unsubstantiated or determined to be false; the number of deaths resulting from child abuse or neglect; the number

of children who received services; agency response times; and the number of workers responsible for child protective service (CPS) functions. The new annual State data report is being combined with the previously existing voluntary Summary Data Component of the National Child Abuse and Neglect Data System. The information collected

will be used to understand better the experiences of children and families served by CPS agencies, and to help guide policy and program development at the National, State and local levels.

Respondents: State, Local or Tribal Govt.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
SDC	56	1	60	3,360

Estimated Total Annual Burden Hours: 3,360.

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Laura Oliven.

Dated: April 13, 1998.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 98-10256 Filed 4-17-98; 8:45 am]

BILLING CODE 4184-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Antiviral Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration

(FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Antiviral Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on May 4, 1998, 8:30 a.m. to 5 p.m.; on May 5, 1998, 8 a.m. to 5 p.m.; and on May 6, 1998, 7:30 a.m. to 5 p.m.

Location: Gaithersburg Hilton, Ballroom, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Rhonda W. Stover or John B. Schupp, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12531. Please call the Information Line for up-to-date information on this meeting.

Agenda: On May 4, 1998, the committee will discuss new drug application (NDA) 20-903, Intron®A/ Rebetol, (interferon alfa-2b, recombinant/ribavirin, Schering Corp.) for the treatment of chronic hepatitis C. On May 5, 1998, the committee will discuss NDA 50-752, Priftin® (rifapentine, Hoechst Marion Roussel, Inc.) for the treatment of pulmonary tuberculosis. On May 6, 1998, the committee will discuss NDA 20-871, NTZ™ (nitazoxanide, UNIMED Pharmaceuticals, Inc.) for the treatment of diarrhea associated with cryptosporidiosis in acquired immune deficiency syndrome (AIDS) patients.

Procedure: On May 4, 1998, from 8:30 a.m. to 5 p.m.; on May 5, 1998, from 8 a.m. to 10:30 a.m. and from 12 m. to 5

p.m.; and on May 6, 1998, from 9 a.m. to 5 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by April 27, 1998. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 m. on May 4 and May 6, 1998. On May 5, 1998, oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before April 27, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On May 5, 1998, from 10:30 a.m. to 12 m., the meeting will be closed for a presentation of confidential material (5 U.S.C. 552(b)(2) and (b)(5)). On May 6, 1998, from 7:30 a.m. to 9 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552(b)(4)). The selected NDA's will be discussed.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 14, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98-10311 Filed 4-17-98; 8:45 am]

BILLING CODE 4160-01-F